Cystic fibrosis microbiology: Advances in antimicrobial therapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to advancements in antimicrobial treatments. New aerosolized antibiotic formulations have recently been introduced (such as inhaled aztreonam), and others are in development (inhaled levofloxacin and liposomal amikacin). Licensed dry powder formulations include tobramycin inhalation powder and dry powder colistimethate (available in Europe). Although inhaled antibiotics have the advantage of being able to deliver high intrapulmonary concentrations of drug, antimicrobial resistance can still develop and is a concern in CF. Antimicrobial resistance might be mitigated by using non-antibiotic treatments, antibiotic adjuvants, which have activity against bacteria. Examples include agents such as gallium, antimicrobial peptides and anti-biofilm compounds such as alginate oligosaccharides (OligoG) and garlic. Vaccination strategies and antibody therapy (IgY) against Pseudomonas aeruginosa have also been attempted to prevent initial infection with this organism in CF. Although aggressive and long-term use of antibiotics has been crucial in slowing lung function decline and improving survival in people with CF, it has added a significant burden of care and associated toxicities in these individuals. Careful surveillance and the use of preventative strategies for antibiotic related toxicity (such as nephrotoxicity and ototoxicity) are essential. Continued development of effective antimicrobial agents that can function in the conditions encountered in the CF lung, such as against bacterial biofilm growth and under anaerobic conditions, is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defensins: antimicrobial peptides of innate immunity
Ganz, T. (2003) · Nature Reviews Immunology · doi:10.1038/nri1180 · Cited by 3,066
Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation
Drenkard, E., & Ausubel, F. M. (2002) · Nature · doi:10.1038/416740a · Cited by 997 · cited 1×
“aeruginosa grow as a biofilm in the airways of CF patients with chronic pulmonary infections [64,65].”
BackgroundDecade-long bacterial community dynamics in cystic fibrosis airways
Zhao, J., Schloss, P. D., Kalikin, L. M., Carmody, L. A., Foster, B. K., Petrosino, J. F., Cavalcoli, J. D., VanDevanter, D. R., Murray, S., Li, J. Z., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120577109 · Cited by 599
Smith, A. L., Fiel, S. B., Mayer-Hamblett, N., Ramsey, B., & Burns, J. L. (2003) · Chest · doi:10.1378/chest.123.5.1495 · Cited by 307
Changes in cystic fibrosis airway microbiota at pulmonary exacerbation
Carmody, L. A., Zhao, J., Schloss, P. D., Petrosino, J. F., Murray, S., Young, V. B., Li, J. Z., & LiPuma, J. J. (2013) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201211-107oc · Cited by 239 · cited 1×
“One group did observe an increase in the relative abundance of Gemella species at exacerbation, suggesting that this anaerobe may be involved in triggering a pulmonary exacerbation [50].”
BackgroundAccurate Assessment of Adherence
Daniels, T., Goodacre, L., Sutton, C., Pollard, K., Conway, S., & Peckham, D. (2011) · Chest · doi:10.1378/chest.09-3074 · Cited by 210
Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
Zemanick, E. T., Harris, J. K., Wagner, B. D., Robertson, C. E., Sagel, S. D., Stevens, M. J., Accurso, F. J., & Laguna, T. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062917 · Cited by 180 · cited 2×
“Antimicrobial treatment of pulmonary exacerbations has been associated with very early effects on the CF microbiome (as early as day 3 of treatment) including significant reductions in the relative abundance of Pseudomonas which correlates with improvements in FEV1% predicted [51,52].”
BackgroundWallock-Richards, D., Doherty, C. J., Doherty, L., Clarke, D. J., Place, M., Govan, J. R. W., & Campopiano, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112726 · Cited by 151 · cited 1×
“cepacia complex, a multiresistant and life-threatening pathogen for which there are few treatments [75].”
BackgroundAdherence with tobramycin inhaled solution and health care utilization
Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-5 · Cited by 95 · cited 1×
“Adherence to therapies is an important component to the improvement of outcomes; high adherence with tobramycin inhalation solution, for example, has been shown to be associated with a decreased risk of hospitalization [86].”
BackgroundMcNamara, P. S., McCormack, P., McDonald, A. J., Heaf, L., & Southern, K. W. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.006 · Cited by 72 · cited 1×
“Using this type of information, it is possible to provide patients with feedback and adjust treatment schedules to hopefully improve compliance [89].”
Background
Cited by
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Progress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options
Chatterjee, M., Anju, C. P., Biswas, L., Anil Kumar, V., Gopi Mohan, C., & Biswas, R. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2015.11.004 · Cited by 312
Cystic fibrosis – Ten promising therapeutic approaches in the current era of care
Somayaji, R., Nichols, D. P., & Bell, S. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1805733 · Cited by 12
Metadata
- Authors
- Waters, V., & Smyth, A.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 14
- Issue
- 5
- Pages
- 551-560
- ISSN
- 1569-1993 (ISSN-L)
- OpenAlex
- W1996197399
- Cited by
- 94
- References
- 10
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cystic fibrosis microbiology: Advances in antimicrobial therapy. https://app.cochat.ai/papers/10.1016/j.jcf.2015.02.005
- The paper
- Waters, V., & Smyth, A. (2015). Cystic fibrosis microbiology: Advances in antimicrobial therapy. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2015.02.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.